WCO IOF-ESCEO 2025: The Long-Term Impact on Bone Mineral Density of Switching from 24-Month Daily Teriparatide to Denosumab or Zoledronic Acid in Postmenopausal Osteoporosis

Presenter: V. Lainis

This retrospective study compared bone mineral density (BMD) changes after switching from 24 months of daily teriparatide (TPTD) to either denosumab (Dmab) or intravenous zoledronic acid (ZOL) in 49 postmenopausal women with severe osteoporosis. 

Patients received Dmab (n=28) or ZOL (n=21) for 36 months, along with calcium and vitamin D. Baseline characteristics and BMD were similar between groups. At 36 months, Dmab produced significantly greater BMD gains than ZOL at lumbar spine (10.25% vs. 1.83%) and total hip (12.35% vs. 3.28%) (p<0.001). 

Switching to Dmab after TPTD is more effective than ZOL for improving BMD at spine and hip.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO IOF-ESCEO 2025), April 10-13, 2025, Rome, Italy.